Connect your AI

Arrowhead Research ARWR Convertible debentures

Convertible debentures at other companies

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's convertible debentures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arrowhead Research's convertible debentures?: Arrowhead Research (ARWR) reported convertible debentures of $681.94M in Q1 2026.